Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
What Makes Nektar (NKTR) a New Buy Stock
01:00pm, Tuesday, 13'th Aug 2024
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
09:04am, Saturday, 10'th Aug 2024
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
12:00pm, Friday, 09'th Aug 2024
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th Aug 2024
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago.
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
04:15pm, Thursday, 08'th Aug 2024
SAN FRANCISCO , Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securiti
SAN FRANCISCO , Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-bas
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism – – IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in Firs
Nektar Management to Present at Upcoming Investor Conferences
06:00pm, Thursday, 30'th May 2024
SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York City on
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
12:35pm, Friday, 10'th May 2024
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
10:40pm, Thursday, 09'th May 2024
Nektar Therapeutics, Inc. (NASDAQ:NKTR ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Vivian Wu - Associate Director, Investor Relations and Corporate Affairs Howard Ro
Nektar Therapeutics Reports First Quarter 2024 Financial Results
04:15pm, Thursday, 09'th May 2024
SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securitie
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
06:00pm, Thursday, 02'nd May 2024
SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fi
TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses AI to transform antibodies into intelligent medicinal solutions, today announc
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 03'rd Apr 2024
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
02:00pm, Friday, 22'nd Mar 2024
SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtua
